- Trial phase
- Approved
- Time to market
- Already approved and commercially launched by Elevar Therapeutics as of September 23, 2026.
- Why 4/10
- LYRFIGTU is already FDA-approved (September 23, 2026) with no pending regulatory decision. The defining binary event has passed. Relay licensed global commercialization rights to Elevar, so the drug contributes to Relay's value only through milestones and royalties, not direct sales. No hard dated catalyst remains for this specific drug within the next 12 months.
LYRFIGTU is already approved and commercialized by Elevar, so there is no upcoming binary catalyst for this specific drug. Watch for Relay's December 14, 2026 ASH presentation and regulatory update on zovegalisib in vascular anomalies (December 14, 2026) and Phase 3 ReDiscover-2 enrollment completion (estimated mid-2027) as the next major stock-moving events for Relay. Milestone/royalty payments from Elevar on LYRFIGTU sales could provide incremental upside but are not a hard catalyst.
Price Chart
Executive Summary
LYRFIGTU (lirafugratinib, formerly RLY-4008) is a highly selective FGFR2 inhibitor approved by the FDA on September 23, 2026 for second-line treatment of FGFR2 fusion-positive cholangiocarcinoma (bile duct cancer). The drug was discovered and developed by Relay Therapeutics (RLAY) but licensed to Elevar Therapeutics in December 2024 for global commercialization. Relay received a $75M upfront payment and is eligible for up to $500M in milestones plus tiered royalties. The approval is a platform validation for Relay's Dynamo discovery engine, but the drug's commercial upside now flows primarily to Elevar. Relay's stock is driven more by its lead pipeline asset zovegalisib (RLY-2608) in Phase 3 for PIK3CA-mutant breast cancer and upcoming ASH data for vascular anomalies on December 14, 2026.
How It Works
LYRFIGTU is an oral pill that selectively blocks FGFR2, a protein on the surface of cancer cells that can drive uncontrolled growth when mutated or fused with other proteins. By blocking FGFR2 with high selectivity (roughly 250-fold over FGFR1 and 5,000-fold over FGFR4), the drug stops cancer growth signals while sparing other similar proteins, reducing side effects. It targets both primary FGFR2 alterations and resistance mutations.
Trial Status
The drug was approved by the FDA on September 23, 2026, based on the Phase 1/2 ReFocus trial (NCT04526106), which showed a 46% confirmed objective response rate and median duration of response of 11.8 months in FGFR2-fusion cholangiocarcinoma patients. The drug was added to NCCN Clinical Practice Guidelines on November 3, 2026.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst for LYRFIGTU specifically (already approved and licensed out). Relay's next major catalysts are the ASH 2026 presentation and regulatory update for zovegalisib on December 14, 2026, and Phase 3 ReDiscover-2 enrollment completion estimated mid-2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Relay Therapeutics, Inc. PRESS-RELEASE RLAY ·Originating report